Research Analysts Offer Predictions for LXEO FY2025 Earnings

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) – Stock analysts at Leerink Partnrs lowered their FY2025 earnings estimates for Lexeo Therapeutics in a report issued on Monday, March 24th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings per share of ($3.18) for the year, down from their prior forecast of ($3.00). The consensus estimate for Lexeo Therapeutics’ current full-year earnings is ($3.14) per share. Leerink Partnrs also issued estimates for Lexeo Therapeutics’ FY2026 earnings at ($2.67) EPS and FY2027 earnings at ($2.63) EPS.

Lexeo Therapeutics (NASDAQ:LXEO) last released its quarterly earnings results on Monday, March 24th. The company reported ($0.78) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.09.

Several other brokerages have also weighed in on LXEO. Chardan Capital reissued a “buy” rating and set a $25.00 price objective on shares of Lexeo Therapeutics in a report on Tuesday. HC Wainwright reiterated a “buy” rating and issued a $23.00 target price on shares of Lexeo Therapeutics in a research note on Wednesday. Royal Bank of Canada lowered their target price on shares of Lexeo Therapeutics from $24.00 to $20.00 and set an “outperform” rating on the stock in a report on Tuesday. Finally, Leerink Partners cut their price target on Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating for the company in a report on Monday. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Lexeo Therapeutics has a consensus rating of “Buy” and a consensus price target of $22.80.

Lexeo Therapeutics Trading Down 10.1 %

Shares of Lexeo Therapeutics stock opened at $3.99 on Thursday. The firm has a market cap of $131.93 million, a PE ratio of -1.26 and a beta of 3.85. Lexeo Therapeutics has a 1 year low of $2.32 and a 1 year high of $19.50. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.95 and a quick ratio of 5.95. The stock has a fifty day moving average price of $4.09 and a 200-day moving average price of $6.65.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of LXEO. Allostery Investments LP purchased a new stake in shares of Lexeo Therapeutics in the fourth quarter worth $33,000. BNP Paribas Financial Markets raised its position in shares of Lexeo Therapeutics by 184.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company’s stock worth $50,000 after purchasing an additional 3,591 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new position in Lexeo Therapeutics in the 4th quarter worth about $46,000. JPMorgan Chase & Co. grew its position in Lexeo Therapeutics by 135.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 10,278 shares of the company’s stock valued at $93,000 after purchasing an additional 5,915 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD purchased a new position in Lexeo Therapeutics in the fourth quarter worth about $69,000. 60.67% of the stock is currently owned by institutional investors.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.